|
|
|
|
|
16.12.25 - 21:30
|
PeopleGrove and CORE Higher Education Group Rebrand as One Company, Launch Unified Website and Product Suite (Business Wire)
|
|
|
WARWICK, R.I.--(BUSINESS WIRE)--Following the merger of PeopleGrove and CORE Higher Education Group in 2024, the combined company (now known as PeopleGrove) has launched a new website, brand, and connected product suite to better reflect the combined capabilities and solutions now available after the last year of integration. Operating under the refreshed PeopleGrove brand and offering the trusted CORE product suite, the unified company delivers a comprehensive platform built to help institutions drive measurable outcomes across experiential learning, accreditation, yield and retention, alumni engagement, career readiness, and mentorship.
This strategic merger brings together two purpose-driven organizations under one brand and one mission: to drive outcomes through meaningful engagement & experiential education by empowering colleges and universities to deliver value, prove impact, and ensure institutional effectiveness across the student and alumni lifecycle.
“Institutions are under growing pressure t...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.12.25 - 21:27
|
Piper Sandler: Ein ungewöhnlicher KI-Trade für 2026 (Der Aktionaer)
|
|
|
Anleger, die vom Boom rund um Künstliche Intelligenz profitieren wollen, müssen ihr Geld nicht zwangsläufig in Halbleiteraktien stecken. Laut der Investmentbank Piper Sandler gibt es eine eher ungewöhnliche, aber vielversprechende Alternative: Warby Parker, ein US-Anbieter von Brillen und Sehhilfen....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.12.25 - 21:24
|
ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m (Business Wire)
|
|
|
Capital increase of approximately 1.8 million euros
Subscription price: 3.10 euros
Extension of visibility until the end of 2026
TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces the launch of a capital increase with the removal of preferential subscription rights (“PSR”) for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new shares at a subscription price of 3.10 euros (the “Issuance”). This capital increase is intended to strengthen the Company's cash position.
Legal framework of the Issue
This transaction is part of a capital increase with cancellation of preferential subscription rights in favor of persons belonging to specific categories, decided today by the Board of Directors, acting ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
